TTBK2

Tau-tubulin kinase 2

5,799 patent compounds predicted against TTBK2, 3,626 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL168084	1.00	16/20
SCHEMBL2881534	0.54	13/20
SCHEMBL2252773	0.66	12/20
SCHEMBL1230553	0.54	11/20
SCHEMBL1230817	0.54	11/20
SCHEMBL1230845	0.51	11/20
SCHEMBL1934806	0.56	10/20
SCHEMBL2371464	0.56	10/20
Nonapyrimine (SCHEMBL2110854)	0.56	10/20
SCHEMBL1230493	0.54	10/20
SCHEMBL2882091	0.65	9/20
SCHEMBL1717446	0.53	9/20
SCHEMBL2877656	0.68	8/20
SCHEMBL1819928	0.52	8/20
SCHEMBL1046996	0.52	8/20
SCHEMBL1229660	0.46	8/20
SCHEMBL859117	0.64	7/20
SCHEMBL102201	0.54	7/20
SCHEMBL191691	0.51	7/20
SCHEMBL1231369	0.48	7/20

Germline variants in TTBK2 on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full TTBK2 gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to TTBK2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Lithium for Prevention of Cognitive Declining in Mood Illnesses	PHASE4	NOT_YET_RECRUITING
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING
Comparative Analysis of the Efficacies in Neoadjuvant Chemotherapy of Breast Cancer	PHASE3	COMPLETED
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast Cancer	PHASE3	SUSPENDED
A Multicenter Study of NAP (AL-108) in Schizophrenia	PHASE2	COMPLETED
Vit D and Peripheral Neuropathy in Taxane Naive Patients	PHASE2	UNKNOWN
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers	PHASE1/PHASE2	NOT_YET_RECRUITING
A Study to Learn About the Safety of BIIB080 Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age	PHASE2	ACTIVE_NOT_RECRUITING
Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors	PHASE2	RECRUITING
Vinorelbine in Relapsed Platinum Resistant or Refractory C5 High Grade Serous, Endometrioid, or Undifferentiated Primary Peritoneum, Fallopian Tube or Ovarian Cancer	PHASE2	UNKNOWN
SB-715992 in Treating Patients With Locally Advanced, Recurrent, or Metastatic Liver Cancer	PHASE2	COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
Study of ABT-751 in Patients With Refractory Hematologic Malignancies	PHASE1	COMPLETED
A Study of Investigational Drug CFI-402257 in Patients With Advanced Solid Tumors	PHASE1	COMPLETED
Effects of Lithium Therapy on Blood-based Therapeutic Targets in Parkinson's Disease.	PHASE1	COMPLETED
AZD1775 for Advanced Solid Tumors	PHASE1	COMPLETED
Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer	PHASE1	ACTIVE_NOT_RECRUITING
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212	EARLY_PHASE1	COMPLETED
Generating Intervals of Reference FFor Early Life Brain Biomarkers.	nan	RECRUITING
Evaluation of a Novel PET Radioligand to Image OGA	nan	COMPLETED
NTRK 1,2,3 Rearrangements in Patients With Solid Tumors	nan	ACTIVE_NOT_RECRUITING
A Retro-/Prospective, Non-interventional, Cohort Study in Adult Patients With Locally Advanced or Metastatic Tumors With a Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion, Treated With Larotrectinib	nan	COMPLETED
Prodromal Model of Parkinson's Disease Confined to The Peripheral Nervous System	nan	ENROLLING_BY_INVITATION
The Relation of Microtubule-Associated Protein 2 and Cell Migration	nan	UNKNOWN
Importance of the Microtubule Cytoskeleton in Oocyte Competence	nan	COMPLETED
Rostock International Parkinson's Disease Study (ROPAD)	nan	COMPLETED
LRRK2 Activity and Markers of Parkinson's Disease in G2385R Carriers	nan	COMPLETED
Natural History Characterization in Symptomatic and Asymptomatic Progranuline Gene Mutation Carriers	nan	COMPLETED
Human CNS Tau Kinetics in Tauopathies	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a TTBK2 binder may also engage these)

Protein	Name	Similarity
Q3UVR3	—	0.997	Q3UVR3 →
Q2PFD7	—	0.991	Q2PFD7 →
Q9NYI0	—	0.990	Q9NYI0 →
P56716	—	0.990	P56716 →
Q3V089	—	0.990	Q3V089 →
Q28DZ0	—	0.990	Q28DZ0 →
Q925H1	—	0.989	Q925H1 →
Q6NS59	—	0.989	Q6NS59 →
Q86XD8	—	0.989	Q86XD8 →
Q90ZS6	—	0.989	Q90ZS6 →
Q9Y2F5	—	0.989	Q9Y2F5 →
Q92628	—	0.989	Q92628 →
Q8C0P0	—	0.989	Q8C0P0 →
Q6ZV73	—	0.988	Q6ZV73 →
MKI67	Proliferation marker protein Ki-67	0.988	landscape →
Q9Z1J2	—	0.988	Q9Z1J2 →
E1BC15	—	0.988	E1BC15 →
Q8MJ06	—	0.988	Q8MJ06 →
Q8MJ05	—	0.988	Q8MJ05 →
O60284	—	0.988	O60284 →
TET1	Methylcytosine dioxygenase TET1	0.988	landscape →
Q5VWN6	—	0.988	Q5VWN6 →
Q3UIZ8	—	0.987	Q3UIZ8 →
Q5DW34	—	0.987	Q5DW34 →
A2AEY4	—	0.987	A2AEY4 →
Q76I79	—	0.987	Q76I79 →
A6QP06	—	0.987	A6QP06 →
Q811D2	—	0.987	Q811D2 →
O88466	—	0.987	O88466 →
Q4V7J0	—	0.987	Q4V7J0 →